DUBLIN, May 8, 2023 /PRNewswire/ -- The "Cancer Cachexia: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Cancer Cachexia Market to Reach $3.5 Billion by 2030
The global market for Cancer Cachexia estimated at US$2.3 Billion in the year 2022, is projected to reach a revised size of US$3.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2022-2030.
Progestogens, one of the segments analyzed in the report, is projected to record a 5.5% CAGR and reach US$1.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 4.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $910.6 Million, While China is Forecast to Grow at 7.3% CAGR
The Cancer Cachexia market in the U.S. is estimated at US$910.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$314 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 4.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.
What`s New for 2023?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Key Topics Covered:
MARKET OVERVIEW
- Cancer: An Insight
- A Prelude to Cancer Cachexia
- Cachexia Treatment
- Pharmacologic Approaches for Clinical Management of Cancer Cachexia
- With IMF Making an Upward Revision of Global GDP for 2022, Companies Remain Bullish About an Economic Comeback
- Cancer Cachexia Market Faces a Challenge Amid the Pandemic
- Pandemic Impact on Cancer Research
- Global Market Prospects and Outlook
- Progestogens Account for a Major Share, Combination Therapies to Drive Growth
- North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
- Competition
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E)
- Recent Market Activity
- Market Challenges
FOCUS ON SELECT PLAYERS Select Competitors (Total 50 Featured)
- AstraZeneca plc
- AVEO Pharmaceuticals, Inc.
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Helsinn Healthcare SA
- INOVIO Pharmaceuticals
- Marsala Biotech Inc.
- MetaFines Co., Ltd.
MARKET TRENDS & DRIVERS
- Rise in Number of Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
- Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
- Promising Treatment Options Drive Market Gains
- NSAID
- Erythropoietin
- Myostatin Inhibitors
- Appetite & Metabolism Modulators
- Cytokine Modulator
- Anabolic Agents
- Combination Therapies
- DNA Link to throw More Light on Cancer Cachexia
- Ageing Demographics to Drive Market Demand
- Cancer Research Spending Continues to Witness Growth
- Pipeline Analysis
- Macimorelin from AEterna Zentaris
- PF- 06946860 from Pfizer
- TCMCB07 from Endevica Bio
- Actimed Therapeutics S-pindolol
- Lenalidomide
- AV-380
- Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
- Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
- Select Key Developments
- Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
- Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
- Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
- Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
- ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
- Uptrend in Healthcare Spending Drives Market Demand
For more information about this report visit https://www.researchandmarkets.com/r/yzps13
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article